Does the Use of Volumetric Modulated Arc Therapy Reduce Gastrointestinal Symptoms after Pelvic Radiotherapy?

Clin Oncol (R Coll Radiol). 2018 Jan;30(1):e22-e28. doi: 10.1016/j.clon.2017.10.016. Epub 2017 Nov 10.

Abstract

Aims: Growing numbers of patients with cancer are surviving after treatment with pelvic radiotherapy. We evaluated the technique of volumetric modulated arc therapy (VMAT), which delivers a decreased dose to the organs at risk. We aimed to determine outcomes of this technique in terms of patient-reported acute toxicity and late effects and correlate the frequency of gastrointestinal symptoms with the volume of bowel receiving radiation dose.

Materials and methods: Patients who were to receive VMAT for gynaecological malignancy completed patient-reported outcomes at baseline, the end of treatment, 8 weeks and 1 year. The rates of patient-reported toxicity were correlated with the volume of bowel irradiated.

Results: The frequencies of patient-reported gastrointestinal symptoms increased in the acute toxicity phase and tended to improve at 1 year, with the exception of faecal incontinence and rectal bleeding (P < 0.05). There was not a strong association between the volume of small bowel that was irradiated (P > 0.05 at all dose levels) and reported toxicity, suggesting that other factors are involved in the development of toxicity.

Conclusion: Although VMAT decreases the dose delivered to the small bowel, this does not translate into a reduction in patient-reported toxicity.

Keywords: Gastrointestinal; VMAT; gynaecological malignancy; toxicity.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gastrointestinal Diseases / pathology
  • Gastrointestinal Diseases / radiotherapy*
  • Genital Neoplasms, Female / pathology
  • Genital Neoplasms, Female / radiotherapy*
  • Humans
  • Middle Aged
  • Pelvis / radiation effects*
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated / methods*
  • Young Adult